Author:
German Danielle,Genberg Becky,Sugarman Olivia,Saloner Brendon,Sawyer Anne,Glick Jennifer L.,Gribbin Molly,Flynn Colin
Abstract
Abstract
Background
Addressing xylazine harms are now a critical harm reduction priority, but relatively little epidemiological information exists to determine prevalence, magnitude, and correlates of xylazine use or related outcomes.
Methods
We conducted a rapid behavioral survey among people who inject drugs (n = 96) in Baltimore November–December 2022. Using a novel indicator of self-reported presumed xylazine effects, we examined prevalence and sociodemographic correlates of past year presumed xylazine effects and association with overdose and wound-related outcomes. Chi-square and descriptive statistics were used to examine bivariate associations overall and separately for those who reported xylazine by name and by reported fentanyl use frequency.
Results
Almost two-thirds (61.5%) reported experiencing xylazine effects. There were no differences by socio-demographics, but xylazine effects were more commonly reported among those who reported injecting alone (66% vs 38%%, p < 0.007) and daily fentanyl use (47% vs 24% p < 0.003). Those reporting xylazine exposure was three times as likely to report overdose (32% vs 11%, p < 0.03) and twice as likely to have used naloxone (78% vs 46%, p < 0.003). They also more commonly reported knowing someone who died of an overdose (92% vs 76%, p < 0.09) and to report an abscess requiring medical attention (36% vs 19%, p < 0.80). These associations were higher among respondents who specifically named xylazine and those who used fentanyl more frequently, but fentanyl frequency did not fully explain the heightened associations with xylazine effects.
Conclusions
This study provides insight into the scope of xylazine exposure and associated health concerns among community-based PWID and suggests measures that may be instrumental for urgently needed research.
Funder
Centers for Disease Control and Prevention
Maryland Department of Health, United States
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. FDA alerts health care professionals of risks to patients exposed to xylazine in illicit drugs [press release]. November 8, 2022 2022.
2. Drug Enforcement Administration. DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine 2023 [Available from: https://www.dea.gov/alert/dea-reports-widespread-threat-fentanyl-mixed-xylazine#:~:text=United%20States%20Drug%20Enforcement%20Administration,-Search&text=.
3. Office of National Drug Control Policy. Biden-Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States 2023 [updated April 12, 2023. Available from: https://www.whitehouse.gov/ondcp/briefing-room/2023/04/12/biden-harris-administration-designates-fentanyl-combined-with-xylazine-as-an-emerging-threat-to-the-united-states/.
4. Kariisa M, Patel P, Smith H, Bitting J. Notes from the field: xylazine detection and involvement in drug overdose deaths—United States, 2019. MMWR Morb Mortal Wkly Rep. 2021;70(37):1300–2.
5. Rodríguez N, Vargas Vidot J, Panelli J, Colón H, Ritchie B, Yamamura Y. GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles. Drug Alcohol Depend. 2008;96(3):290-3
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献